The Gene Box
Business Case

For Diagnostic Labs: How to Escape the Test Price War

Every year the tests you run get cheaper to copy and harder to differentiate. The way out isn't a cheaper test — it's owning the layer above it: the interpretation.

The Gene Box··4 min read

Ask a lab owner what happened to margins on routine panels over the last decade and you'll hear the same story: the tests didn't get worse, they got common. When every competitor runs the same assay on the same class of analyser, procurement compares the only variable left — price. The way out is not a cheaper test. It's selling something a price list can't capture.

Why good labs lose on price

Here is the uncomfortable mechanism. In most of the markets we operate in, nothing on a quotation distinguishes a rigorous report from a thin one. In India there is no CLIA equivalent and NABL accreditation is voluntary — so when two quotes land on a procurement desk, quality is invisible and price is the only signal that survives the comparison. Losing that comparison doesn't mean your lab is worse. It means the thing you're better at was never visible in the first place.

If the difference between you and the cheap option only shows up after purchase, procurement is right to ignore it.

The layer above the test

A test result is a number. What clinicians and end-clients actually pay for is the answer: what these numbers mean together, for this person, with what confidence. That interpretation layer is where differentiation lives, because it cannot be copied by buying the same analyser. Our platform fuses the layers you already produce — DNA, gut microbiome, blood — into one reasoned profile, with every interpretation traced to curated evidence and reviewed and signed off by a qualified human. Decision-support for the treating professional, not a verdict from a black box.

150,000Curated references behind interpretations
1,200+Validated biomarkers
125K+Genomes decoded since 2015

What it looks like operationally

Your wet-lab keeps doing what it does. The interpretation platform sits on top: your test output goes in, a branded multi-omic report comes back under your name, from roughly $3–5 per interpreted report. Most labs start light — an interpretation overlay on panels they already run — then add fused multi-omic products as clients ask for them. Because the lab already exists, going live is an integration project, not a build. (For the full build-vs-buy comparison, see in-house vs white-label, or explore the Evolveme platform.)

Making quality legible before the price conversation

The deeper win is commercial. A lab selling interpreted, evidence-traced reports has something to show a prospect that a price list can't flatten: run the interpretation on their own past cases, show what the cheaper report would have missed, and put the citations where a non-specialist can check them. That is how quality becomes visible before the pricing conversation — and how the conversation stops being about price. We operate this model with 39 partners across 11 countries, under ISO 9001:2015 (pursuing ISO 13485), GDPR-compliant.

One structural point worth naming: we run no consumer store. Your clients are never our customers — the brand on the report, and the relationship behind it, stay yours.

If you run a diagnostic lab and want to see what your existing test menu looks like with an interpretation layer on top, book a 30-minute demo — we'll walk through the economics against your actual volumes.

Keep reading

See it under your brand

Book a 30-minute demo and we'll show you the exact products, economics, and go-live path for your practice.